These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 3299589)

  • 1. Management of iron overload in dialysis patients.
    Winchester JF
    Semin Nephrol; 1986 Dec; 6(4 Suppl 1):22-6. PubMed ID: 3299589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Iron-overload in patients on maintenance hemodialysis: diagnostic criteria, indications and treatment by desferrioxamine (author's transl)].
    Simon P; Bonn F; Guezennec M; Tanquerel T; Ksang
    Nephrologie; 1981; 2(4):165-70. PubMed ID: 7329501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis and treatment of iron overload in paediatric patients on chronic haemodialysis.
    Eijgenraam FJ; Donckerwolcke RA; van Dijken PJ
    Pediatr Nephrol; 1988 Jul; 2(3):303-8. PubMed ID: 3153030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detoxification in hemosiderosis.
    Simon P
    Blood Purif; 1985; 3(1-3):75-88. PubMed ID: 3913449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemosiderosis in a patient on regular hemodialysis: treatment by desferrioxamine.
    Baker LR; Barnett MD; Brozovic B; Cattell WR; Ackrill P; McAlister J; Nimmon C
    Clin Nephrol; 1976 Jul; 6(1):326-8. PubMed ID: 954239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Failure of deferoxamine to improve iron overload in chronic hemodialysis patients.
    Roxe DM; Krumlovsky FA; Del Greco F; Fitzsimons E
    Int J Artif Organs; 1990 Apr; 13(4):211-7. PubMed ID: 2115505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy and monitoring of hypersiderosis in chronic renal insufficiency.
    Hilfenhaus M; Koch KM; Bechstein PB; Schmidt H; Fassbinder W; Baldamus CA
    Contrib Nephrol; 1984; 38():167-74. PubMed ID: 6713893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.
    Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2006; 30(2):219-27. PubMed ID: 16798647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of iron overload in children and adolescents on chronic haemodialysis.
    Eijgenraam FJ; Donckerwolcke RA
    Eur J Pediatr; 1990 Feb; 149(5):359-62. PubMed ID: 2311634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron overload disorders: natural history, pathogenesis, diagnosis, and therapy.
    McLaren GD; Muir WA; Kellermeyer RW
    Crit Rev Clin Lab Sci; 1983; 19(3):205-66. PubMed ID: 6373141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics and efficacy of deferoxamine in iron-overloaded hemodialysis patients.
    Stivelman J; Schulman G; Fosburg M; Lazarus JM; Hakim RM
    Kidney Int; 1989 Dec; 36(6):1125-32. PubMed ID: 2601259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous chelation therapy during transplantation for thalassemia.
    Gaziev D; Giardini C; Angelucci E; Polchi P; Galimberti M; Baronciani D; Erer B; Maiello A; Lucarelli G
    Haematologica; 1995; 80(4):300-4. PubMed ID: 7590497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity.
    McCarthy JT; Milliner DS; Johnson WJ
    Q J Med; 1990 Mar; 74(275):257-76. PubMed ID: 2117295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The value of nuclear magnetic resonance in the study of iron overload in thalassemia patients].
    Perrimond H; Chagnon C; Moulanier I; Michel G; Guidicelli H; Bernard PJ
    Ann Pediatr (Paris); 1991 Mar; 38(3):175-84. PubMed ID: 2039185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron removal by desferrioxamine in patients on chronic hemodialysis--kinetic study and long-term results.
    Kovarik J; Irschik H; Graf H; Woloszczuk W; Meisinger V; Linkesch W; Stummvoll HK
    Contrib Nephrol; 1985; 49():44-55. PubMed ID: 3830570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron chelation by deferoxamine in sickle cell patients with severe transfusion-induced hemosiderosis: a randomized, double-blind study of the dose-response relationship.
    Silliman CC; Peterson VM; Mellman DL; Dixon DJ; Hambidge KM; Lane PA
    J Lab Clin Med; 1993 Jul; 122(1):48-54. PubMed ID: 8320490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent developments in iron chelation therapy.
    Cario H; Janka-Schaub G; Janssen G; Jarisch A; Strauss G; Kohne E
    Klin Padiatr; 2007; 219(3):158-65. PubMed ID: 17525910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemosiderosis in a dialysis patient: treatment with hemofiltration and deferoxamine chelation therapy.
    McCarthy JT; Libertin CR; Mitchell JC; Fairbanks VF
    Mayo Clin Proc; 1982 Jul; 57(7):439-41. PubMed ID: 7087549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden.
    Voskaridou E; Komninaka V; Karavas A; Terpos E; Akianidis V; Christoulas D
    Transfusion; 2014 Mar; 54(3):646-9. PubMed ID: 23834310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
    Kolnagou A; Yazman D; Economides C; Eracleous E; Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.